#RXST

StockTitan

@stocktitan.net

2 months ago

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational

#RXST RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

www.stocktitan.net/news/RXST/rx-sight-inc-a...

StockTitan

@stocktitan.net

2 months ago

RxSight, Inc. Announces Chief Financial Officer Transition RxSight (NASDAQ:RXST) announced that Shelley Thunen, its Chief Financial Officer, is transitioning from the CFO role and will remain with the company until the sooner of her successor's appointment or January 31, 2026. Ms. Thunen has agreed to support RxSight as a consultant after the transition.The release highlights Ms. Thunen's nearly decade of service, her role in the company's 2021 IPO, and operational achievements under her finance leadership, including more than 1,100 light-adjustable intraocular devices (LDDs) in the field and over 250,000 procedures performed. The CEO and board expressed gratitude for her contributions.

#RXST RxSight, Inc. Announces Chief Financial Officer Transition

www.stocktitan.net/news/RXST/rx-sight-inc-a...

StockTitan

@stocktitan.net

4 months ago

RxSight, Inc. Reports Third Quarter 2025 Financial Results RxSight (Nasdaq: RXST) reported third quarter 2025 results: Q3 revenue $30.3M (down 14% YoY) driven by 26,045 LAL lenses sold (+6% procedure volume) and 25 LDD devices sold (-69%). Gross margin was 80% (+844 bps YoY). The company narrowed full‑year 2025 revenue guidance to $125.0M–$130.0M, raised full‑year gross margin guidance to 76%–77%, and kept operating expense guidance at $145M–$155M (including stock‑based comp of $30M–$32M). Cash and short‑term investments totaled $227.5M as of September 30, 2025.

#RXST RxSight, Inc. Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/RXST/rx-sight-inc-r...

StockTitan

@stocktitan.net

4 months ago

RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting RxSight (Nasdaq: RXST) will host multiple Live Learning Sessions at AAO 2025 in Orlando, Oct 18–20, at Booth #2931. Sessions feature surgeons sharing real-world experience with the Light Adjustable Lens, focusing on clinical advantages and economic implications of adjustability.Scheduled talks run Oct 18 (10:00 AM–3:00 PM) and Oct 19 (10:00 AM–1:00 PM) and cover topics such as ROI, career impact, premium lens adoption, patient-centered outcomes, and practical counseling for Light Adjustable Lens patients.

#RXST RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting

www.stocktitan.net/news/RXST/rx-sight-inc-t...

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Small-cap stocks with improving money flow, Tue Aug 19th - #RXST #WTBA #SSPS #REPL #PLPC #MFH #LFST #PTY #PRLB #IIIN #BRSP #AGM - More: crystalequityresearch.com/leading-indi... - #smallcap

Thiard News@F4F

@newsen.bsky.social

6 months ago

DJS Law Group Investigates Potential Securities Fraud by RxSight, Inc. DJS Law Group is looking into claims against RxSight, Inc. regarding potential securities fraud violations that may have impacted investors significantly.

DJS Law Group Investigates Potential Securities Fraud by RxSight, Inc. #USA #DJS_Law_Group #Eastchester #RxSight #RXST

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

8 months ago

RxSight Falls 34% After Hours Following Revenue Warning RxSight Inc. (RXST) shares plunged 34.32% in after-hours. The decline to $8.40 follows a downward revision of its 2025 revenue forecast. read...

#benzinga #neuro #Biotech #Equities #healthcare #NASDAQ […]

[Original post on benzinga.com]

StockTitan

@stocktitan.net

8 months ago

RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance RxSight (NASDAQ: RXST), an ophthalmic medical device company, reported disappointing preliminary Q2 2025 results and significantly lowered its full-year guidance. Revenue is expected to be $33.6 million, down 4% year-over-year and 11% sequentially.The company sold 27,380 Light Adjustable Lenses (up 13% YoY but down 1% QoQ) and 40 Light Delivery Devices (down 49% YoY and 45% QoQ). The installed base grew 34% YoY to 1,084 LDDs.RxSight revised its 2025 guidance downward, now expecting revenue of $120-130 million (previously $160-175 million), while increasing gross margin guidance to 72-74% and reducing operating expense projections to $145-155 million.

#RXST RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance

www.stocktitan.net/news/RXST/rx-sight-inc-a...

StockTitan

@stocktitan.net

10 months ago

RxSight, Inc. Reports First Quarter 2025 Financial Results RxSight (RXST) reported strong Q1 2025 financial results with revenue of $37.9 million, up 28% year-over-year. The company sold 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedures, and added 73 Light Delivery Devices (LDD™s), expanding the installed base to 1,044 units. Gross profit reached $28.3 million (74.8% margin), while net loss improved to $(8.2) million or $(0.20) per share. The company maintained its 2025 guidance, projecting revenue of $160-175 million and operating expenses of $150-160 million. Management highlighted strong customer enthusiasm and strategic growth opportunities through service center expansion and international approvals.

#RXST RxSight, Inc. Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/RXST/rx-sight-inc-r...

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

Small-cap stocks with strong volume declines, Thu Apr 3rd - #SONM #FBLA #CJET #ATPC #WBTN #SBT #RXST #LGO #INV #DTI #CLBK #ALDX #CPRI #SPRU #FC - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

11 months ago

RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance RxSight (NASDAQ: RXST) announced preliminary Q1 2025 revenue of $37.9 million, showing 28% year-over-year growth but a 6% decrease from Q4 2024. The company reported selling 27,579 Light Adjustable Lenses, a 36% increase from Q1 2024, and 73 Light Delivery Devices, expanding the installed base to 1,044 LDDs (43% growth year-over-year).Due to headwinds in the premium IOL market and broader economy, RxSight revised its 2025 guidance downward. The new full-year revenue guidance is $160.0-175.0 million (down from $185.0-197.0 million), representing 14-25% growth. Operating expenses are now projected at $150.0-160.0 million, reduced from $165.0-170.0 million, including non-cash stock-based compensation of $27.0-30.0 million.

#RXST RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

www.stocktitan.net/news/RXST/rx-sight-inc-a...

StockTitan

@stocktitan.net

1 year ago

RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance RxSight (RXST) reported strong Q4 and full-year 2024 financial results. Q4 revenue reached $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The LDD installed base expanded to 971 units.Full-year 2024 revenue grew 57% to $139.9 million, with 98,055 LALs and 305 LDDs sold. Gross profit margin improved to 71.6% in Q4 2024, up from 61.8% in Q4 2023. The company reported a reduced Q4 net loss of $(5.9) million compared to $(9.2) million in Q4 2023.For 2025, RxSight reaffirmed guidance projecting revenue of $185.0-197.0 million (32-41% growth), gross margin of 71-73%, and operating expenses of $165.0-170.0 million.

#RXST RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance

www.stocktitan.net/news/RXST/rx-sight-inc-r...

StockTitan

@stocktitan.net

1 year ago

RxSight Delivers 57% Revenue Surge to $140M as Light Adjustable Lens Adoption Soars RxSight reports strong preliminary Q4 results with 41% revenue growth, expanding its Light Adjustable Lens presence to 15% of North American cataract surgeons.

#RXST RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance

www.stocktitan.net/news/RXST/rx-sight-inc-a...

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #RXST ) (RXST) Pivots Trading Plans and Risk Controls

#StockMarket #News